Business Insider

Allergan's RESTASIS MULTIDOSE™ (Cyclosporine Ophthalmic Emulsion) 0.05% Approved in Canada

-- New Delivery System Will Now Provide RESTASIS ® in a Preservative Free, Easy-to-Use, Multi-Dose Bottle-- -- RESTASIS the Only* Health Canada Approved Treatment to Help Patients Produce More of ...
Yahoo Finance

How Back-to-Back RESTASIS and PROAIR Generics At Amneal Pharmaceuticals (AMRX) Has Changed Its Investment Story

Amneal Pharmaceuticals recently received U.S. FDA approvals for its generic versions of RESTASIS® (cyclosporine ophthalmic emulsion 0.05%) and PROAIR® HFA (albuterol sulfate inhalation aerosol 90 mcg) ...
Monthly Prescribing Reference

First Generic Version of Restasis Gets FDA Approval

Credit: Getty Images. Cyclosporine ophthalmic emulsion is indicated to increase tear production in patients whose tear production is presumed to be suppressed due to ocular inflammation associated ...
Medical News Today

Restasis (cyclosporine) eye drops

Restasis generic Restasis is a brand-name drug that contains the active drug cyclosporine. This active drug is also available as a generic medication called cyclosporine ophthalmic emulsion. A generic ...
Business Wire

Aurinia Announces Voclosporin Ophthalmic Solution Demonstrates Statistically Superior Efficacy Versus Restasis® in a Phase 2 Head-to-Head Study for the Treatment of Dry Eye ...

RESTASIS® and RESTASIS MULTIDOSE™ Ophthalmic Emulsion help increase your eyes' natural ability to produce tears, which may be reduced by inflammation due to Chronic Dry Eye.
WGHP

Viatris is First to Receive FDA Approval of Generic Restasis® (Cyclosporine Ophthalmic Emulsion 0.05%) to Treat Dry Eye Disease

PITTSBURGH, Feb. 3, 2022 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) today announced that its subsidiary, Mylan Pharmaceuticals Inc., has received approval from the U.S. Food and Drug Administration ...
Business Wire

Aurinia to Hold Conference Call and Webcast to Discuss Results of Phase 2 Head-to-Head Study of Voclosporin Ophthalmic Solution versus Restasis® for the Treatment of Dry Eye ...

VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH/TSX:AUP), a clinical stage biopharmaceutical company focused on the global immunology market, today announced it ...